Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCN1 | O60741 | 1/20 | 0.30 |
| ▸ | HCN3 | Q9P1Z3 | 1/20 | 0.30 |
| ▸ | HCN2 | Q9UL51 | 1/20 | 0.30 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5888096 | 0.80 | OPRM1 (0.33) | OPRM1OPRK1OPRL1 | |
| SCHEMBL31479155 | 0.80 | EPHX1 (0.38) | — | |
| SCHEMBL6138297 | 0.77 | MEN1 (0.34) | OPRM1OPRK1OPRL1 | |
| SCHEMBL338063 | 0.77 | SOS1 (0.33) | — | |
| SCHEMBL5481700 | 0.77 | SOS1 (0.33) | — | |
| SCHEMBL6698499 | 0.77 | KDM4E (0.31) | — | |
| SCHEMBL9562288 | 0.72 | CHRNA7 (0.36) | OPRM1OPRK1OPRL1 | |
| SCHEMBL20851506 | 0.71 | OPRM1 (0.36) | HCN1HCN4OPRM1OPRK1OPRL1 | |
| SCHEMBL1088158 | 0.71 | HCN1 (0.31) | HCN1HCN3HCN2HCN4 | |
| SCHEMBL31511619 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4696695-A1 | ANTIBIOTIC RIFABUTIN ANALOGS | BioVersys AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20250320225-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY INC (US) | 2025-10-16 | — | — | US | disclosed |
| WO-2025215110-A1 | NEW AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS SOS1 INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2025-10-16 | — | — | WO | disclosed |
| US-20250255869-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA | KURA ONCOLOGY INC (US) | 2025-08-14 | — | — | US | disclosed |
| US-20240358703-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA | KURA ONCOLOGY, INC. | 2024-10-31 | — | — | US | disclosed |
| WO-2024208228-A1 | NOVEL COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) | 2024-10-10 | — | — | WO | disclosed |
| US-11944627-B2 | Methods for treating hematological malignancies and Ewing's sarcoma | KURA ONCOLOGY, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| CN-117298275-A | Method for treating hematological malignancies and ewing's sarcoma | 库拉肿瘤学公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230405008-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN | KURA ONCOLOGY, INC. | 2023-12-21 | — | — | US | disclosed |
| CN-110691779-B | Method for treating hematological malignancies and ewing's sarcoma | 库拉肿瘤学公司 | 2023-10-10 | — | — | CN | disclosed |
| EP-3601249-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA | Kura Oncology, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| CN-110691779-A | Method for treating hematologic malignancies and ewing's sarcoma | 库拉肿瘤学公司 | 2020-01-14 | — | — | CN | disclosed |
| US-20190092784-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. | 2019-03-28 | — | — | US | disclosed |
| US-20190092784-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. | 2019-03-28 | — | — | US | disclosed |
| EP-3429591-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | Kura Oncology, Inc. (US) | 2019-01-23 | — | — | EP | disclosed |
| WO-2018175746-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA | KURA ONCOLOGY, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018106820-A1 | METHODS OF PROMOTING BETA CELL PROLIFERATION | KURA ONCOLOGY, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106820-A1 | METHODS OF PROMOTING BETA CELL PROLIFERATION | KURA ONCOLOGY, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2017161028-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017161028-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358703-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA | MEN1, DIAPH1, EWSR1 | HCN1 3911/4885HCN3 4276/4885HCN2 3440/4885 |
| US-20250320225-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | MLLT1, MEN1, MLLT3 | HCN1 4848/4885HCN3 4859/4885HCN2 4752/4885 |
| US-20190092784-A1 | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | MLLT1, MEN1, MLLT3 | HCN1 4809/4885HCN3 4806/4885HCN2 4724/4885 |
| US-20250255869-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND EWING'S SARCOMA | MEN1, DIAPH1, EWSR1 | HCN1 3911/4885HCN3 4276/4885HCN2 3440/4885 |
| US-20230405008-A1 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH INHIBITORS OF MENIN | MEN1, MCL1, XPOT | HCN1 3091/4885HCN3 3898/4885HCN2 2917/4885 |
| US-11944627-B2 | Methods for treating hematological malignancies and Ewing's sarcoma | MEN1, DIAPH1, EWSR1 | HCN1 4169/4885HCN3 4419/4885HCN2 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.